California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 18, 2016 -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix Pharmaceuticals”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will announce fourth quarter and fiscal year 2015 ended December 31, 2015 financial results and host a conference call and webcast on Thursday, March 3.
Conference Call & Webcast
Thursday, March 3, 2016 @ 8am Eastern Time
| Toll Free: | 888-329-8862 | ||||
| International: | 719-325-2361 | ||||
| Conference ID: | 1046957 | ||||
| Webcast: | http://public.viavid.com/index.php?id=118418 | ||||
| Replays, through March 17th | |||||
| Toll-Free: | 877-870-5176 | ||||
| International: | 858-384-5517 | ||||
| Conference ID: | 1046957 | ||||
About Foamix Pharmaceuticals Ltd.
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX102 for the treatment of impetigo, FMX 103 for the treatment of rosacea, and FDX104, our doxycycline foam for the management of acne-like rash, induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including Bayer HealthCare, Merz, Allergan and Prestium.
Contact: Ilan Hadar, CFO Foamix Pharmaceuticals Ltd. +972-8-9316233 [email protected] US Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 [email protected]
